Jiachen Tan , Qinzheng Xu , Nuruliarizki Shinta Pandupuspitasari , Faheem Ahmed Khan , Di Wu , Fei Sun , Chunjie Huang
{"title":"非编码rna -糖酵解轴在癌症治疗耐药中的作用:对治疗方案机制的洞察。","authors":"Jiachen Tan , Qinzheng Xu , Nuruliarizki Shinta Pandupuspitasari , Faheem Ahmed Khan , Di Wu , Fei Sun , Chunjie Huang","doi":"10.1016/j.bcp.2025.117286","DOIUrl":null,"url":null,"abstract":"<div><div>Despite advancements in cancer therapy, including radiotherapy and chemotherapy, resistance to cancer treatment remains a significant clinical challenge. Metabolic reprogramming and dysfunctional glycolysis, a defining characteristic of cancer cells, are commonly observed in drug-resistant cancer cells. Besides glycolytic enzymes, several signaling molecules—including EGFR, HIF-1α, AMPK, and β-catenin—are involved in the regulation of glycolysis and play crucial roles in mediating resistance to cancer therapy. Numerous studies have elucidated the pivotal role of non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), in the modulation of cancer drug resistance. miRNAs dually regulate glycolysis—some inhibit glycolysis to overcome therapy resistance, while others promote glycolysis, inducing resistance in cancer cells. Recent investigations have underscored the critical function of competitive endogenous RNAs (ceRNAs) in modulating glycolytic pathways, indicating circRNA/lncRNA–miRNA–mRNA as an important regulatory network in cancer therapy resistance. Exosomal ncRNAs are another mediator of cancer therapy resistance; depending on the specific ncRNAs they carry, they can either promote or suppress glycolysis. In the final section, we demonstrated that herbal medicine can successfully mitigate drug resistance in cancer by modulating the ncRNA-glycolysis axis.</div></div>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"242 ","pages":"Article 117286"},"PeriodicalIF":5.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Non-coding RNAs-glycolysis axis in cancer therapy resistance: Insight into mechanism to therapeutic solution\",\"authors\":\"Jiachen Tan , Qinzheng Xu , Nuruliarizki Shinta Pandupuspitasari , Faheem Ahmed Khan , Di Wu , Fei Sun , Chunjie Huang\",\"doi\":\"10.1016/j.bcp.2025.117286\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Despite advancements in cancer therapy, including radiotherapy and chemotherapy, resistance to cancer treatment remains a significant clinical challenge. Metabolic reprogramming and dysfunctional glycolysis, a defining characteristic of cancer cells, are commonly observed in drug-resistant cancer cells. Besides glycolytic enzymes, several signaling molecules—including EGFR, HIF-1α, AMPK, and β-catenin—are involved in the regulation of glycolysis and play crucial roles in mediating resistance to cancer therapy. Numerous studies have elucidated the pivotal role of non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), in the modulation of cancer drug resistance. miRNAs dually regulate glycolysis—some inhibit glycolysis to overcome therapy resistance, while others promote glycolysis, inducing resistance in cancer cells. Recent investigations have underscored the critical function of competitive endogenous RNAs (ceRNAs) in modulating glycolytic pathways, indicating circRNA/lncRNA–miRNA–mRNA as an important regulatory network in cancer therapy resistance. Exosomal ncRNAs are another mediator of cancer therapy resistance; depending on the specific ncRNAs they carry, they can either promote or suppress glycolysis. In the final section, we demonstrated that herbal medicine can successfully mitigate drug resistance in cancer by modulating the ncRNA-glycolysis axis.</div></div>\",\"PeriodicalId\":8806,\"journal\":{\"name\":\"Biochemical pharmacology\",\"volume\":\"242 \",\"pages\":\"Article 117286\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biochemical pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0006295225005519\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0006295225005519","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Non-coding RNAs-glycolysis axis in cancer therapy resistance: Insight into mechanism to therapeutic solution
Despite advancements in cancer therapy, including radiotherapy and chemotherapy, resistance to cancer treatment remains a significant clinical challenge. Metabolic reprogramming and dysfunctional glycolysis, a defining characteristic of cancer cells, are commonly observed in drug-resistant cancer cells. Besides glycolytic enzymes, several signaling molecules—including EGFR, HIF-1α, AMPK, and β-catenin—are involved in the regulation of glycolysis and play crucial roles in mediating resistance to cancer therapy. Numerous studies have elucidated the pivotal role of non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), in the modulation of cancer drug resistance. miRNAs dually regulate glycolysis—some inhibit glycolysis to overcome therapy resistance, while others promote glycolysis, inducing resistance in cancer cells. Recent investigations have underscored the critical function of competitive endogenous RNAs (ceRNAs) in modulating glycolytic pathways, indicating circRNA/lncRNA–miRNA–mRNA as an important regulatory network in cancer therapy resistance. Exosomal ncRNAs are another mediator of cancer therapy resistance; depending on the specific ncRNAs they carry, they can either promote or suppress glycolysis. In the final section, we demonstrated that herbal medicine can successfully mitigate drug resistance in cancer by modulating the ncRNA-glycolysis axis.
期刊介绍:
Biochemical Pharmacology publishes original research findings, Commentaries and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics.
The journal''s target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process.
All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complimentary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review.
While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.